These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
241 related articles for article (PubMed ID: 24106222)
1. Liver gene therapy by lentiviral vectors reverses anti-factor IX pre-existing immunity in haemophilic mice. Annoni A; Cantore A; Della Valle P; Goudy K; Akbarpour M; Russo F; Bartolaccini S; D'Angelo A; Roncarolo MG; Naldini L EMBO Mol Med; 2013 Nov; 5(11):1684-97. PubMed ID: 24106222 [TBL] [Abstract][Full Text] [Related]
2. Effective gene therapy for haemophilic mice with pathogenic factor IX antibodies. Markusic DM; Hoffman BE; Perrin GQ; Nayak S; Wang X; LoDuca PA; High KA; Herzog RW EMBO Mol Med; 2013 Nov; 5(11):1698-709. PubMed ID: 24106230 [TBL] [Abstract][Full Text] [Related]
3. Platelet gene therapy by lentiviral gene delivery to hematopoietic stem cells restores hemostasis and induces humoral immune tolerance in FIX(null) mice. Chen Y; Schroeder JA; Kuether EL; Zhang G; Shi Q Mol Ther; 2014 Jan; 22(1):169-77. PubMed ID: 24042561 [TBL] [Abstract][Full Text] [Related]
4. Efficient induction of immune tolerance to coagulation factor IX following direct intramuscular gene transfer. Cohn EF; Zhuo J; Kelly ME; Chao HJ J Thromb Haemost; 2007 Jun; 5(6):1227-36. PubMed ID: 17362228 [TBL] [Abstract][Full Text] [Related]
5. Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial. Monahan PE; Sun J; Gui T; Hu G; Hannah WB; Wichlan DG; Wu Z; Grieger JC; Li C; Suwanmanee T; Stafford DW; Booth CJ; Samulski JJ; Kafri T; McPhee SW; Samulski RJ Hum Gene Ther; 2015 Feb; 26(2):69-81. PubMed ID: 25419787 [TBL] [Abstract][Full Text] [Related]
6. Integration-deficient lentiviral vectors expressing codon-optimized R338L human FIX restore normal hemostasis in Hemophilia B mice. Suwanmanee T; Hu G; Gui T; Bartholomae CC; Kutschera I; von Kalle C; Schmidt M; Monahan PE; Kafri T Mol Ther; 2014 Mar; 22(3):567-574. PubMed ID: 23941813 [TBL] [Abstract][Full Text] [Related]
7. AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice. Crudele JM; Finn JD; Siner JI; Martin NB; Niemeyer GP; Zhou S; Mingozzi F; Lothrop CD; Arruda VR Blood; 2015 Mar; 125(10):1553-61. PubMed ID: 25568350 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of adeno-associated viral vectors based on serotype 8 and 9 vs. lentiviral vectors for hemophilia B gene therapy. Vandendriessche T; Thorrez L; Acosta-Sanchez A; Petrus I; Wang L; Ma L; DE Waele L; Iwasaki Y; Gillijns V; Wilson JM; Collen D; Chuah MK J Thromb Haemost; 2007 Jan; 5(1):16-24. PubMed ID: 17002653 [TBL] [Abstract][Full Text] [Related]
11. Hyperfunctional coagulation factor IX improves the efficacy of gene therapy in hemophilic mice. Cantore A; Nair N; Della Valle P; Di Matteo M; Màtrai J; Sanvito F; Brombin C; Di Serio C; D'Angelo A; Chuah M; Naldini L; Vandendriessche T Blood; 2012 Nov; 120(23):4517-20. PubMed ID: 23043073 [TBL] [Abstract][Full Text] [Related]
12. Factor IX: Insights from knock-out and genetically engineered mice. Monahan PE Thromb Haemost; 2008 Oct; 100(4):563-75. PubMed ID: 18841277 [TBL] [Abstract][Full Text] [Related]
13. The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle gene therapy. Finn JD; Nichols TC; Svoronos N; Merricks EP; Bellenger DA; Zhou S; Simioni P; High KA; Arruda VR Blood; 2012 Nov; 120(23):4521-3. PubMed ID: 22919027 [TBL] [Abstract][Full Text] [Related]
15. Bioengineered factor IX molecules with increased catalytic activity improve the therapeutic index of gene therapy vectors for hemophilia B. Brunetti-Pierri N; Grove NC; Zuo Y; Edwards R; Palmer D; Cerullo V; Teruya J; Ng P Hum Gene Ther; 2009 May; 20(5):479-85. PubMed ID: 19196177 [TBL] [Abstract][Full Text] [Related]
16. FIX-Triple, a gain-of-function factor IX variant, improves haemostasis in mouse models without increased risk of thrombosis. Kao CY; Lin CN; Yu IS; Tao MH; Wu HL; Shi GY; Yang YL; Kao JT; Lin SW Thromb Haemost; 2010 Aug; 104(2):355-65. PubMed ID: 20539913 [TBL] [Abstract][Full Text] [Related]
17. Baboon envelope pseudotyped lentiviral vectors efficiently transduce human B cells and allow active factor IX B cell secretion in vivo in NOD/SCIDγc Levy C; Fusil F; Amirache F; Costa C; Girard-Gagnepain A; Negre D; Bernadin O; Garaulet G; Rodriguez A; Nair N; Vandendriessche T; Chuah M; Cosset FL; Verhoeyen E J Thromb Haemost; 2016 Dec; 14(12):2478-2492. PubMed ID: 27685947 [TBL] [Abstract][Full Text] [Related]
18. Immune tolerance induction to factor IX through B cell gene transfer: TLR9 signaling delineates between tolerogenic and immunogenic B cells. Wang X; Moghimi B; Zolotukhin I; Morel LM; Cao O; Herzog RW Mol Ther; 2014 Jun; 22(6):1139-1150. PubMed ID: 24609143 [TBL] [Abstract][Full Text] [Related]
19. Sustained expression of coagulation factor IX by modified cord blood-derived mesenchymal stromal cells. Dodd M; Marquez-Curtis L; Janowska-Wieczorek A; Hortelano G J Gene Med; 2014; 16(5-6):131-42. PubMed ID: 24947827 [TBL] [Abstract][Full Text] [Related]
20. Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. Mount JD; Herzog RW; Tillson DM; Goodman SA; Robinson N; McCleland ML; Bellinger D; Nichols TC; Arruda VR; Lothrop CD; High KA Blood; 2002 Apr; 99(8):2670-6. PubMed ID: 11929752 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]